Artiva Biotherapeutics (NASDAQ:ARTV) Director Purchases $1,151,558.10 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 120,582 shares of the company’s stock in a transaction that occurred on Tuesday, July 21st. The shares were acquired at an average cost of $9.55 per share, with a total value of $1,151,558.10. Following the purchase, the director owned 17,098,479 shares in the company, valued at $163,290,474.45. This represents a 0.71% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 24th, Ra Capital Management, L.P. bought 41,319 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.99 per share, for a total transaction of $412,776.81.
• On Thursday, July 23rd, Ra Capital Management, L.P. purchased 59,880 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $9.96 per share, with a total value of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. purchased 84,124 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $9.93 per share, with a total value of $835,351.32.
• On Friday, July 10th, Ra Capital Management, L.P. purchased 15,102 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.97 per share, with a total value of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. acquired 6,552 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. purchased 15,414 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. acquired 391,019 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.57 per share, with a total value of $3,351,032.83.

Artiva Biotherapeutics Trading Up 4.1%

Artiva Biotherapeutics stock opened at $10.43 on Friday. Artiva Biotherapeutics, Inc. has a 12-month low of $2.22 and a 12-month high of $14.53. The stock has a market cap of $257.80 million, a P/E ratio of -2.95 and a beta of 2.18. The company has a 50-day moving average price of $8.96 and a 200 day moving average price of $7.49.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter valued at about $79,000. Qube Research & Technologies Ltd acquired a new stake in Artiva Biotherapeutics in the second quarter valued at approximately $58,000. Jane Street Group LLC acquired a new stake in Artiva Biotherapeutics in the second quarter valued at approximately $67,000. Bridgeway Capital Management LLC purchased a new position in Artiva Biotherapeutics in the second quarter worth approximately $53,000. Finally, BNP Paribas Financial Markets lifted its stake in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ARTV. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Wedbush increased their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.